BACKGROUND: Caloric restriction alone has been shown to improve insulin action and fasting glucose metabolism; however, the mechanism by which this occurs remains uncertain. OBJECTIVE: We sought to quantify the effect of caloric restriction on β cell function and glucose metabolism in people with type 2 diabetes. METHODS: Nine subjects (2 men, 7 women) with type 2 diabetes [BMI (in kg/m(2)): 40.6 ± 1.4; age: 58 ± 3 y; glycated hemoglobin: 6.9% ± 0.2%] were studied using a triple-tracer mixed meal after withdrawal of oral diabetes therapy. The oral minimal model was used to measure β cell function. Caloric restriction limited subjects to a pureed diet (<900 kcal/d) for the 12 wk of study. The studies were repeated after 6 and 12 wk of caloric restriction. RESULTS: Fasting glucose concentrations decreased significantly from baseline after 6 wk of caloric restriction with no further reduction after a further 6 wk of caloric restriction (9.8 ± 1.3, 5.9 ± 0.2, and 6.2 ± 0.3 mmol/L at baseline and after 6 and 12 wk of caloric restriction, respectively; P = 0.01) because of decreased fasting endogenous glucose production (EGP: 20.4 ± 1.1, 16.2 ± 0.8, and 17.4 ± 1.1 μmol · kg(-1) · min(-1) at baseline and after 6 and 12 wk of caloric restriction, respectively; P = 0.03). These changes were accompanied by an improvement in β cell function measured by the disposition index (189 ± 51, 436 ± 68, and 449 ± 67 10(-14) dL · kg(-1) · min(-2) · pmol(-1) at baseline and after 6 and 12 wk of caloric restriction, respectively; P = 0.01). CONCLUSIONS: Six weeks of caloric restriction lowers fasting glucose and EGP with accompanying improvements in β cell function in people with type 2 diabetes. An additional 6 wk of caloric restriction maintained the improvement in glucose metabolism. This trial was registered at clinicaltrials.gov as NCT01094054.
BACKGROUND: Caloric restriction alone has been shown to improve insulin action and fasting glucose metabolism; however, the mechanism by which this occurs remains uncertain. OBJECTIVE: We sought to quantify the effect of caloric restriction on β cell function and glucose metabolism in people with type 2 diabetes. METHODS: Nine subjects (2 men, 7 women) with type 2 diabetes [BMI (in kg/m(2)): 40.6 ± 1.4; age: 58 ± 3 y; glycated hemoglobin: 6.9% ± 0.2%] were studied using a triple-tracer mixed meal after withdrawal of oral diabetes therapy. The oral minimal model was used to measure β cell function. Caloric restriction limited subjects to a pureed diet (<900 kcal/d) for the 12 wk of study. The studies were repeated after 6 and 12 wk of caloric restriction. RESULTS: Fasting glucose concentrations decreased significantly from baseline after 6 wk of caloric restriction with no further reduction after a further 6 wk of caloric restriction (9.8 ± 1.3, 5.9 ± 0.2, and 6.2 ± 0.3 mmol/L at baseline and after 6 and 12 wk of caloric restriction, respectively; P = 0.01) because of decreased fasting endogenous glucose production (EGP: 20.4 ± 1.1, 16.2 ± 0.8, and 17.4 ± 1.1 μmol · kg(-1) · min(-1) at baseline and after 6 and 12 wk of caloric restriction, respectively; P = 0.03). These changes were accompanied by an improvement in β cell function measured by the disposition index (189 ± 51, 436 ± 68, and 449 ± 67 10(-14) dL · kg(-1) · min(-2) · pmol(-1) at baseline and after 6 and 12 wk of caloric restriction, respectively; P = 0.01). CONCLUSIONS: Six weeks of caloric restriction lowers fasting glucose and EGP with accompanying improvements in β cell function in people with type 2 diabetes. An additional 6 wk of caloric restriction maintained the improvement in glucose metabolism. This trial was registered at clinicaltrials.gov as NCT01094054.
Authors: Claudio Cobelli; Gianna Maria Toffolo; Chiara Dalla Man; Marco Campioni; Paolo Denti; Andrea Caumo; Peter Butler; Robert Rizza Journal: Am J Physiol Endocrinol Metab Date: 2007-03-06 Impact factor: 4.310
Authors: James M Isbell; Robyn A Tamboli; Erik N Hansen; Jabbar Saliba; Julia P Dunn; Sharon E Phillips; Pamela A Marks-Shulman; Naji N Abumrad Journal: Diabetes Care Date: 2010-04-05 Impact factor: 19.112
Authors: Gerlies Bock; Chiara Dalla Man; Francesco Micheletto; Rita Basu; Paula D Giesler; Jeanette Laugen; Carolyn F Deacon; Jens J Holst; Gianna Toffolo; Claudio Cobelli; Robert A Rizza; Adrian Vella Journal: Clin Endocrinol (Oxf) Date: 2009-12-18 Impact factor: 3.478
Authors: Chiara Dalla Man; Gerlies Bock; Paula D Giesler; Denise B Serra; Monica Ligueros Saylan; James E Foley; Michael Camilleri; Gianna Toffolo; Claudio Cobelli; Robert A Rizza; Adrian Vella Journal: Diabetes Care Date: 2008-10-17 Impact factor: 17.152
Authors: Marion L Vetter; Thomas A Wadden; Karen L Teff; Zahra F Khan; Raymond Carvajal; Scott Ritter; Reneé H Moore; Jesse L Chittams; Alex Iagnocco; Kenric Murayama; Gary Korus; Noel N Williams; Michael R Rickels Journal: Diabetes Date: 2014-09-09 Impact factor: 9.461
Authors: Meera Shah; Marcello C Laurenti; Chiara Dalla Man; Jing Ma; Claudio Cobelli; Robert A Rizza; Adrian Vella Journal: Metabolism Date: 2018-12-23 Impact factor: 8.694
Authors: Greg M Kowalski; Steven Hamley; Ahrathy Selathurai; Joachim Kloehn; David P De Souza; Sean O'Callaghan; Brunda Nijagal; Dedreia L Tull; Malcolm J McConville; Clinton R Bruce Journal: Sci Rep Date: 2016-06-07 Impact factor: 4.379
Authors: Cassandra B Higgins; Yiming Zhang; Allyson L Mayer; Hideji Fujiwara; Alicyn I Stothard; Mark J Graham; Benjamin M Swarts; Brian J DeBosch Journal: JCI Insight Date: 2018-08-23
Authors: Nadezda V Andrianova; Marina I Buyan; Anastasia K Bolikhova; Dmitry B Zorov; Egor Y Plotnikov Journal: Front Physiol Date: 2021-07-06 Impact factor: 4.566